Clinical outcome after NK-cell infusion of 1 patient with AML harboring inv(16) in early molecular relapse. Because adequate numbers of donor NK cells were available, a second NK-cell infusion, after immunosuppressive chemotherapy, was performed at the time of the second relapse. The figure shows the value of both WT1 and CBF molecular transcript at different time points.